Second or greater stem cell transplant using reduced intensity conditioning

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This treatment guideline focuses on administering a second or greater allogeneic hematopoietic stem cell transplant (HSCT) for patients with hematologic disorders who did not achieve adequate donor-derived engraftment after a previous transplant. The approach utilizes a reduced intensity conditioning regimen that includes busulfan, fludarabine, and low-dose total body irradiation to enhance the chances of successful engraftment. The study involves the collection of routine clinical data to monitor outcomes and transplant-related endpoints, but does not include a research element beyond this data collection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of any disease for which a second or greater hematopoietic stem cell transplant is needed due to insufficient donor chimerism following hematopoietic recovery after previous HSCT. Determination of "insufficiency of donor chimerism" will be made by the treating transplant physician. Occasionally donor derived engraftment may be present, but sustained aplasia or failed recovery of sufficient hematopoiesis requires administration of a second graft. This intervention may be used for both situations.
* Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program

  * Transplantation using sufficiently matched related donors (such as matched siblings) or unrelated donors will be considered. Both granulocyte-colony stimulating factor (GCSF) stimulated peripheral blood grafts and bone marrow grafts will be considered, although bone marrow will be the priority.
  * Cord blood grafts, both related and unrelated, are also eligible. As this protocol will use a reduced intensity regimen, this protocol will use the current recommendations of the University of Minnesota for choosing cord blood grafts. If a single cord blood unit cell dose is insufficient, double cord transplantation should be considered if sufficiently matched cord blood units are available. The priority of choosing cord blood donors is based on the current institutional recommendations.
  * Exclusion of Metabolic Disorder or other Inherited Disorder Carrier Status from related donor and unrelated cord blood grafts as appropriate for primary disease.

At the discretion of the treating transplant physician, an allograft from the previous donor may be used, if available.

* Age, Performance Status, Consent

  * Age: 0 to 55 years
  * Consent: voluntary written consent (adult or parental/guardian)

Exclusion Criteria:

* Previous irradiation that precludes the safe administration of an additional dose of 200 cGy of total body irradiation (TBI). Radiation Oncology will evaluate all patients who have had previous radiation therapy or TBI for approval to receive an additional 200 cGy of TBI
* Pregnant or breastfeeding
* Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted
* HIV positive
* While it would be advantageous to begin therapy on this second transplant regimen \> 6 months following a prior myeloablative regimen or \>2 months after a reduced intensity regimen, it is recognized that there are circumstances where this may not be practical.

Where it's running

• Masonic Cancer Center, University of Minnesota
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Troy Lund, M.D., Ph.D. — Masonic Cancer Center, University of Minnesota
• Study coordinator: Troy Lund, M.D., Ph.D.
• Email: mill4991@umn.edu
• Phone: 612-625-2508

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lusutrombopag to help platelet recovery after allogeneic stem cell transplant

  This will test whether the oral drug lusutrombopag helps restore platelet counts in adults after HLA haploidentical allogeneic stem cell transplantation for blood disorders.

  Recruiting The General Hospital of Western Theater Command · Chengdu · NCT07483385

• HOPE Biobank: connecting blood disease patients through stem cell transplant and gene therapy samples

  This study will collect blood and other biospecimens along with clinical data from people undergoing stem cell transplant or gene therapy for non-cancer blood diseases to build a large biobank for future research.

  Recruiting at 14 sites Medical College of Wisconsin · Duarte, California and 13 other locations · NCT07227155

• V-IMMUNE 5% intravenous immunoglobulin for people with primary immunodeficiency

  This study will try V-IMMUNE®, a 5% IVIG given every three weeks, as replacement therapy for people aged 2 and older who already receive IVIG to see if it prevents serious infections and is safe over one year.

  Recruiting Phase 3 On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. · Recife, Pernanbuco · NCT06954441

• Donor transplant for high risk blood disorders

  This study is testing if a stem cell transplant from a matched sibling can help people with high-risk blood disorders like sickle cell disease and thalassemia feel better.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06872333

• Using CD45RA Depleted Stem Cells to Prevent Infections After Transplant

  This study is testing whether using special stem cells can help patients with high-risk leukemia recover their immune system faster and prevent infections after a stem cell transplant.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839456

• Investigating genetic factors in blood disorders

  This study is trying to find out how genes affect blood disorders like sickle cell disease and thalassemia by looking at the DNA of many people with these conditions.

  Recruiting at 17 sites Cyprus Institute of Neurology and Genetics · Boston, Massachusetts and 25 other locations · NCT05799118

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.